{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:41:19Z","timestamp":1771051279932,"version":"3.50.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T00:00:00Z","timestamp":1447977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0143207","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T19:50:22Z","timestamp":1448049022000},"page":"e0143207","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis"],"prefix":"10.1371","volume":"10","author":[{"given":"Peng","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meizhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqiong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haihua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinying","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Gavine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,11,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"J Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"ref2","first-page":"19","article-title":"Burden of gastrointestinal cancer in Asia; an overview","volume":"8","author":"MA Pourhoseingholi","year":"2015","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ctrv.2010.01.005","article-title":"Advanced gastric cancer\u2014slow but steady progress","volume":"36","author":"DG Power","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/1097-0142(19890215)63:4<791::AID-CNCR2820630431>3.0.CO;2-W","article-title":"Gastric cancer heterogeneity","volume":"63","author":"X de Aretxabala","year":"1989","journal-title":"Cancer"},{"key":"ref5","first-page":"61","article-title":"Heterogeneity of DNA ploidy in gastric cancer","volume":"4","author":"Y Yonemura","year":"1992","journal-title":"Anal Cell Pathol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12013-011-9286-1","article-title":"Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens","volume":"62","author":"J Yang","year":"2012","journal-title":"Cell Biochem Biophys"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.bjc.6605912","article-title":"How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine","volume":"103","author":"M Gerlinger","year":"2010","journal-title":"Br J Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/embor.2012.61","article-title":"Cancer chromosomal instability: therapeutic and diagnostic challenges","volume":"13","author":"N McGranahan","year":"2012","journal-title":"EMBO Rep"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"W Tai","year":"2010","journal-title":"J Control Release"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"YJ Bang","year":"2010","journal-title":"Lancet"},{"key":"ref11","first-page":"501","article-title":"Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET","volume":"6","author":"L Naldini","year":"1991","journal-title":"Oncogene"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"E Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molonc.2014.08.015","article-title":"Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models","volume":"9","author":"PR Gavine","year":"2015","journal-title":"Mol Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","article-title":"FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547","volume":"19","author":"L Xie","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref15","first-page":"7","article-title":"Towards the goal of personalized medicine in gastric cancer\u2014time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway","volume":"16","author":"J Lee","year":"2013","journal-title":"Discov Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bjc.2013.802","article-title":"FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study","volume":"110","author":"X Su","year":"2014","journal-title":"Br J Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.1038\/sj.onc.1210872","article-title":"Activation and regulation of ATM kinase activity in response to DNA double-strand breaks","volume":"26","author":"JH Lee","year":"2007","journal-title":"Oncogene"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrc1011","article-title":"ATM and related protein kinases: safeguarding genome integrity","volume":"3","author":"Y Shiloh","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/sj.bjc.6690209","article-title":"Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia","volume":"79","author":"HM Inskip","year":"1999","journal-title":"Br J Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s12253-014-9776-8","article-title":"Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins","volume":"20","author":"Q Ye","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1756-9966-32-95","article-title":"ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition","volume":"32","author":"MS Gilardini Montani","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.4161\/cc.29212","article-title":"Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines","volume":"13","author":"E Kubota","year":"2014","journal-title":"Cell Cycle"},{"issue":"12","key":"ref23","first-page":"B42","article-title":"ATM deficiency sensitizes gastric cancer cells to the PARP inhibitior olaparib","volume":"8","author":"XN Guo","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/1535-7163.MCT-12-0950","article-title":"RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib","volume":"12","author":"A Min","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/gastro\/got022","article-title":"Biomarkers in precision therapy in colorectal cancer","volume":"1","author":"MS Reimers","year":"2013","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/bjc.2014.61","article-title":"HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma","volume":"110","author":"YJ Liu","year":"2014","journal-title":"Br J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1158\/2159-8290.CD-11-0289","article-title":"Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer","volume":"1","author":"Y Feng","year":"2011","journal-title":"Cancer Discov"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/jco.2013.31.15_suppl.tps4155","article-title":"MetGastric: A randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction","volume":"31","author":"D Cunningham","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000346034","article-title":"Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients","volume":"80","author":"HS Kim","year":"2013","journal-title":"Pathobiology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0143207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T16:52:47Z","timestamp":1599843167000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0143207"}},"subtitle":[],"editor":[{"given":"Daniele","family":"Generali","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,20]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0143207","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,20]]}}}